![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: PLXDC1 |
Gene summary for PLXDC1 |
![]() |
Gene information | Species | Human | Gene symbol | PLXDC1 | Gene ID | 57125 |
Gene name | plexin domain containing 1 | |
Gene Alias | TEM3 | |
Cytomap | 17q12 | |
Gene Type | protein-coding | GO ID | GO:0001525 | UniProtAcc | Q8IUK5 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
57125 | PLXDC1 | HCC1 | Human | Liver | HCC | 3.69e-11 | 3.45e+00 | 0.5336 |
57125 | PLXDC1 | HCC2 | Human | Liver | HCC | 7.09e-19 | 9.88e-01 | 0.5341 |
57125 | PLXDC1 | HCC5 | Human | Liver | HCC | 3.46e-26 | 1.12e+00 | 0.4932 |
57125 | PLXDC1 | Pt13.a | Human | Liver | HCC | 2.05e-03 | 1.27e-01 | 0.021 |
57125 | PLXDC1 | Pt13.b | Human | Liver | HCC | 8.07e-21 | 4.79e-01 | 0.0251 |
57125 | PLXDC1 | ATC12 | Human | Thyroid | ATC | 1.04e-12 | 2.85e-01 | 0.34 |
57125 | PLXDC1 | ATC13 | Human | Thyroid | ATC | 3.07e-41 | 6.99e-01 | 0.34 |
57125 | PLXDC1 | ATC2 | Human | Thyroid | ATC | 2.49e-06 | 6.89e-01 | 0.34 |
57125 | PLXDC1 | ATC4 | Human | Thyroid | ATC | 1.79e-15 | 3.67e-01 | 0.34 |
57125 | PLXDC1 | ATC5 | Human | Thyroid | ATC | 4.73e-42 | 7.61e-01 | 0.34 |
Page: 1 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PLXDC1 | SNV | Missense_Mutation | c.682N>A | p.Asp228Asn | p.D228N | Q8IUK5 | protein_coding | tolerated(0.2) | possibly_damaging(0.536) | TCGA-A2-A04W-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
PLXDC1 | SNV | Missense_Mutation | rs779072478 | c.398C>T | p.Ser133Leu | p.S133L | Q8IUK5 | protein_coding | tolerated(0.09) | probably_damaging(0.944) | TCGA-A2-A0SY-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | arimidex | SD |
PLXDC1 | SNV | Missense_Mutation | rs750612805 | c.1041T>G | p.Cys347Trp | p.C347W | Q8IUK5 | protein_coding | deleterious(0) | probably_damaging(0.988) | TCGA-BH-A0HO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
PLXDC1 | deletion | Frame_Shift_Del | novel | c.1458delC | p.Ser487ArgfsTer22 | p.S487Rfs*22 | Q8IUK5 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
PLXDC1 | SNV | Missense_Mutation | rs748638753 | c.499N>T | p.Arg167Trp | p.R167W | Q8IUK5 | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
PLXDC1 | SNV | Missense_Mutation | c.98N>T | p.Ser33Phe | p.S33F | Q8IUK5 | protein_coding | tolerated(0.72) | benign(0) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
PLXDC1 | SNV | Missense_Mutation | rs748638753 | c.499N>T | p.Arg167Trp | p.R167W | Q8IUK5 | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-AA-3845-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
PLXDC1 | SNV | Missense_Mutation | rs146173470 | c.689N>A | p.Arg230His | p.R230H | Q8IUK5 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AD-5900-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
PLXDC1 | SNV | Missense_Mutation | c.1050N>T | p.Glu350Asp | p.E350D | Q8IUK5 | protein_coding | deleterious(0) | possibly_damaging(0.829) | TCGA-CM-6674-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
PLXDC1 | SNV | Missense_Mutation | rs143709538 | c.1010N>A | p.Arg337His | p.R337H | Q8IUK5 | protein_coding | deleterious(0) | benign(0.303) | TCGA-AG-3892-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |